Allspring Global Investments Holdings LLC Sells 33,397 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,774,605 shares of the medical research company's stock after selling 33,397 shares during the period. Allspring Global Investments Holdings LLC owned approximately 3.61% of Charles River Laboratories International worth $259,075,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Rothschild Investment LLC lifted its stake in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the period. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $37,000. GeoWealth Management LLC boosted its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International in the fourth quarter valued at $48,000. Finally, Tortoise Investment Management LLC raised its stake in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Up 2.0%

Charles River Laboratories International stock traded up $3.00 during trading hours on Tuesday, reaching $154.73. 1,007,463 shares of the company's stock traded hands, compared to its average volume of 1,023,635. The firm has a market capitalization of $7.60 billion, a price-to-earnings ratio of -238.05, a PEG ratio of 5.08 and a beta of 1.48. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The firm's 50 day moving average is $137.10 and its 200-day moving average is $153.12.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm posted $2.27 earnings per share. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CRL. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Barclays raised their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Friday. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).